Biocartis Group, a molecular diagnostics company, has established a US subsidiary, Biocartis US, and has appointed Vishal Sikri as its US general manager. These announcements represent the next steps of the company’s US strategy following its commercialisation agreement with Thermo Fisher Scientific last year.
US flag
“I am very pleased to be leading the team that will build the commercial activities of Biocartis in the US, an important new market for the company,” said Sikri. “I truly believe that with Idylla we will make a difference in the US market where there is a pressing need for easy, rapid and highly accurate oncology diagnostic solutions.”
Roll-out of the Idylla platform and its accompanying assays in the US is anticipated in the second half of this year.